TRM12 Antibody

What is TRM12/TRMT12 and what is its primary function in cellular biochemistry?

TRM12/TRMT12 (tRNA methyltransferase 12 homolog) is an S-adenosyl-L-methionine-dependent transferase that functions as a critical component of the wybutosine biosynthesis pathway. The protein plays an essential role in tRNA modification, particularly in the production of wybutosine, which is a hypermodified guanosine found at the 3'-position adjacent to the anticodon of eukaryotic phenylalanine tRNA .

The enzyme specifically catalyzes the transfer of the alpha-amino-alpha-carboxypropyl (acp) group from S-adenosyl-L-methionine to the C-7 position of 4-demethylwyosine (imG-14) to produce wybutosine-86 . This modification is crucial for stabilizing codon-anticodon interactions during decoding on the ribosome, thereby impacting protein synthesis quality control . The human version of TRM12 consists of 448 amino acids with a molecular mass of approximately 50.2 kilodaltons and is expressed across multiple tissue types, with particularly high levels observed in liver and brain tissues .

What experimental applications are suitable for TRM12/TRMT12 antibodies?

TRM12/TRMT12 antibodies are versatile tools that can be employed in several key experimental applications:

The selection of the optimal application depends on the specific research question. Western blotting is particularly useful for determining protein expression levels and molecular weight verification, while immunocytochemistry provides valuable insights into subcellular localization patterns. Several commercial antibodies have been validated for detecting TRMT12 in human samples, with some showing cross-reactivity with mouse and rat orthologs based on sequence homology .

How should I select between polyclonal and monoclonal TRM12/TRMT12 antibodies?

The choice between polyclonal and monoclonal antibodies should be guided by your specific experimental requirements:

Polyclonal Antibodies:

• Recognize multiple epitopes on the TRMT12 protein, potentially increasing detection sensitivity

• May provide more robust detection if protein conformation is altered by experimental conditions

• Examples include rabbit polyclonal antibodies that target recombinant fragments or synthetic peptides of human TRMT12

• Particularly useful for initial characterization studies or when antibody sensitivity is the primary concern

Monoclonal Antibodies:

• Offer superior specificity for a single epitope, reducing background and cross-reactivity

• Provide better reproducibility between experiments and antibody lots

• Available options like the OTI3D1 clone can provide consistent results across different applications

• Preferable for quantitative analyses or when comparing TRMT12 levels between multiple samples

For novel research applications, it may be beneficial to validate findings using both antibody types to ensure robust and reproducible results.

What is the expected molecular weight of TRMT12 protein in Western blot applications?

When performing Western blot analysis for TRMT12, researchers should expect to observe a band at approximately 45-50 kDa, which aligns with the calculated molecular weight of 50 kDa based on the 448 amino acid sequence .

Western blot validation data from multiple antibody suppliers consistently show bands in this range. For instance, anti-TRMT12 antibody ab113103 detects a band at the predicted size of 50 kDa in K562 cell lysates . Similarly, Proteintech's antibody (84167-3-RR) detects TRMT12 at 45-50 kDa in various human cell lines including HeLa, K-562, MCF-7, U2OS, U-521, and MDA-MB-231 cells .

It's important to note that post-translational modifications or tissue-specific processing may occasionally result in slight variations in the observed molecular weight. Therefore, appropriate positive controls should be included in Western blot experiments to verify band specificity.

How can I validate the specificity of TRMT12 antibodies in my experimental system?

Rigorous validation of TRMT12 antibodies is essential for ensuring experimental reliability. Consider implementing the following multi-faceted approach:

• Blocking Peptide Competition Assay: Incubate the TRMT12 antibody with excess immunizing peptide prior to application. The disappearance or significant reduction of signal, as demonstrated with ab113103 where the 50 kDa band was eliminated when using the blocking peptide with K562 cell lysate, confirms specificity .

• Genetic Validation:

  • CRISPR/Cas9 knockout or siRNA knockdown of TRMT12

  • Overexpression of tagged TRMT12 constructs

  • Both approaches should show corresponding changes in antibody signal intensity

• Cross-Species Reactivity Assessment: Test the antibody on samples from multiple species to confirm cross-reactivity claims. While many TRMT12 antibodies are validated for human samples, predicted reactivity with mouse and rat samples should be experimentally verified due to sequence homology .

• Multiple Antibody Comparison: Use antibodies targeting different epitopes of TRMT12. Similar patterns across different antibodies increase confidence in specificity.

• Mass Spectrometry Validation: For definitive confirmation, perform immunoprecipitation followed by mass spectrometry to verify that the antibody is capturing TRMT12 protein.

What are the optimal cell and tissue types for studying TRMT12 expression and function?

TRMT12 expression varies across different tissue types, making certain experimental systems more suitable than others for functional studies:

Cell Lines with Validated TRMT12 Expression:

• K562 (human leukemia): Consistently shows robust TRMT12 expression in Western blot analyses

• HeLa (cervical cancer): Demonstrates detectable TRMT12 expression

• MCF-7 and MDA-MB-231 (breast cancer): Both exhibit TRMT12 expression, potentially enabling comparative studies

• U2OS and U-521 (osteosarcoma and glioblastoma): Show expression that can be detected by Western blot

Tissue Types with High TRMT12 Expression:

• Liver and brain tissues show particularly high expression levels, making them suitable for ex vivo or primary cell studies

• Lung cancer tissue has been validated for TRMT12 immunohistochemistry studies

For functional studies, consider that TRMT12 plays a role in the wybutosine biosynthesis pathway that impacts tRNA modification and protein synthesis quality control. Therefore, experimental systems where protein synthesis regulation is being studied (such as differentiating cells or cells under stress conditions) may provide valuable insights into TRMT12 function.

What methods can be employed to study TRMT12's role in the wybutosine biosynthesis pathway?

Investigating TRMT12's role in wybutosine biosynthesis requires specialized approaches that integrate tRNA modification analysis with protein function studies:

• tRNA Modification Analysis:

  • High-performance liquid chromatography coupled with mass spectrometry (HPLC-MS) to detect changes in wybutosine-modified tRNAPhe

  • Primer extension analysis to map modification sites on tRNA

  • Next-generation sequencing approaches optimized for tRNA modification detection

• Enzymatic Activity Assays:

  • In vitro reconstitution of wybutosine biosynthesis using purified components

  • S-adenosyl-L-methionine binding and utilization assays

  • Transfer of alpha-amino-alpha-carboxypropyl group to substrate analogs

• Genetic Approaches:

  • CRISPR/Cas9-mediated mutation of catalytic residues to establish structure-function relationships

  • Complementation studies in model organisms with TRMT12 orthologs (such as yeast TYW2)

  • Analysis of phenotypes associated with TRMT12 deficiency, particularly focusing on protein synthesis fidelity

• Interaction Studies:

  • Co-immunoprecipitation to identify proteins that interact with TRMT12

  • Proximity labeling approaches (BioID, APEX) to map the wybutosine synthesis complex

  • Previous interactome mapping has identified TRMT12 protein interactions that may provide insights into its functional network

These approaches collectively enable a comprehensive understanding of TRMT12's enzymatic function and its broader role in maintaining translation fidelity through tRNA modification.

How can I troubleshoot cross-reactivity issues with TRMT12 antibodies?

Cross-reactivity problems can significantly impact experimental results when working with TRMT12 antibodies. The following methodological approaches can help identify and mitigate these issues:

• Epitope Analysis:

  • Compare the immunogen sequence used to generate the antibody with homologous proteins

  • Antibodies targeting the recombinant fragment corresponding to amino acids 212-399 of human TRMT12 may have different cross-reactivity profiles than those targeting other regions

  • Consider antibodies generated against synthetic peptides within human TRMT12, which may offer higher specificity

• Optimization Strategies:

  • Titrate antibody concentration to find the optimal signal-to-noise ratio

  • Increase washing stringency in immunoblotting and immunostaining protocols

  • Use alternative blocking agents if standard BSA or milk proteins are insufficient

• Validation Controls:

  • Include lysates from TRMT12 knockout or knockdown samples as negative controls

  • Test multiple antibodies targeting different TRMT12 epitopes

  • For antibodies with predicted cross-species reactivity, verify using appropriate positive controls

• Sample Preparation Refinements:

  • Subcellular fractionation to enrich for compartments where TRMT12 is predominantly located

  • Optimize protein extraction methods to preserve TRMT12 while minimizing extraction of cross-reactive proteins

  • Consider immunoprecipitation followed by Western blotting to increase specificity

• Technical Alternatives:

  • For critical experiments where antibody specificity is questionable, consider using tagged TRMT12 constructs and detecting the tag instead

  • Mass spectrometry-based approaches can provide antibody-independent verification of TRMT12 expression and modification state

What are the emerging research areas involving TRMT12 and how can antibodies facilitate these studies?

Recent advances in understanding tRNA modifications and translation regulation have opened new research avenues involving TRMT12. These emerging areas can be explored using appropriate antibody-based techniques:

• TRMT12 in Cancer Biology:

  • Several antibodies have been validated in cancer cell lines including K562, HeLa, MCF-7, and MDA-MB-231

  • IHC validation in lung cancer tissues suggests potential roles in malignancy

  • Research opportunities include examining TRMT12 expression across cancer types and assessing its potential as a biomarker

• Stress Response and Translation Regulation:

  • TRMT12's role in tRNA modification may influence how cells respond to various stressors

  • Antibodies can be used to track TRMT12 localization and expression changes under stress conditions

  • Co-localization studies with stress granule or P-body markers can reveal potential roles in mRNA fate determination

• Integration with Multi-Omics Approaches:

  • The All of Us Research Program and similar large-scale genomic databases now include GWAS and RVAS results that may reveal phenotypic associations with TRMT12 variants

  • Antibodies can help validate findings from genetic association studies by examining protein expression consequences of genetic variants

• Post-Translational Modifications of TRMT12:

  • Phospho-specific or other modification-specific antibodies could reveal regulatory mechanisms controlling TRMT12 function

  • Temporal dynamics of TRMT12 modifications during cell cycle or development represent unexplored research territory

• TRMT12 in Neurodegenerative Disorders:

  • Given high expression in brain tissue , potential roles in neuronal function warrant investigation

  • Antibodies optimized for brain tissue applications could facilitate studies in neurodegeneration models

These research directions highlight the continued importance of well-validated TRMT12 antibodies as tools to advance understanding of fundamental biological processes and disease mechanisms.

What are the optimal storage and handling conditions for maintaining TRMT12 antibody activity?

Proper storage and handling of TRMT12 antibodies is critical for maintaining their specificity and sensitivity across experiments:

Most commercial TRMT12 antibodies are supplied as concentrated stock solutions that should be diluted to working concentrations immediately before use. For reconstituted lyophilized antibodies (such as those from AOBIOUS), follow manufacturer instructions to reconstitute in the specified volume (e.g., 200 μL of sterile H2O) .

How do I optimize Western blot protocols specifically for TRMT12 detection?

Achieving optimal Western blot results for TRMT12 detection requires attention to several key protocol elements:

• Sample Preparation:

  • Cell lysis buffers containing protease inhibitors are essential to prevent TRMT12 degradation

  • Loading 15-20 μg of total protein per lane is typically sufficient for detection in cell lines with normal TRMT12 expression

• Gel Electrophoresis and Transfer:

  • 10-12% polyacrylamide gels provide optimal resolution around the 45-50 kDa range where TRMT12 migrates

  • Semi-dry transfer systems with PVDF membranes have been successfully used in published protocols

• Blocking and Antibody Incubation:

  • 5% non-fat dry milk or BSA in TBST is suitable for blocking

  • Primary antibody dilutions range from 1:200 to 1:4000 depending on the specific antibody

  • Overnight incubation at 4°C often yields the best signal-to-noise ratio

• Detection and Visualization:

  • HRP-conjugated secondary antibodies followed by enhanced chemiluminescence detection

  • Expected band should appear at 45-50 kDa, with validation controls showing band disappearance with blocking peptide

• Troubleshooting Guidelines:

  • If signal is weak, consider longer exposure times or increased antibody concentration

  • High background may require more stringent washing or reduced antibody concentration

  • Multiple bands may indicate protein degradation or post-translational modifications

Following a standardized Western blot protocol, such as the one available from Proteintech for antibody 84167-3-RR, can provide a good starting point for optimization .

What are the key considerations for immunohistochemistry applications using TRMT12 antibodies?

Successful immunohistochemistry (IHC) with TRMT12 antibodies requires attention to tissue preparation, antibody selection, and detection methods:

• Tissue Preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues require appropriate antigen retrieval

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is a recommended starting point

  • Frozen sections may provide better epitope preservation for certain antibodies

• Antibody Selection and Dilution:

  • Rabbit polyclonal antibodies have been validated for IHC applications, particularly in human lung cancer samples

  • Starting dilutions of 1:50-1:300 are recommended, with optimization needed for each tissue type

  • Consider antibodies specifically validated for IHC rather than assuming WB-validated antibodies will perform well

• Detection Systems:

  • HRP-polymer detection systems offer good sensitivity with minimal background

  • DAB (3,3'-diaminobenzidine) provides a brown precipitate that contrasts well with hematoxylin counterstain

  • For multiplex staining, consider fluorescent secondary antibodies with appropriate controls for autofluorescence

• Controls and Validation:

  • Positive control tissues should include liver or brain, where TRMT12 expression is known to be high

  • Negative controls should include primary antibody omission and ideally tissues from TRMT12 knockdown models

  • Blocking peptide controls can confirm specificity of staining patterns

• Interpretation Guidelines:

  • TRMT12 has been reported to show both nuclear and cytoplasmic localization

  • Scoring systems should consider both staining intensity and percentage of positive cells

  • Correlation with other methods (e.g., RNA expression data) strengthens interpretation validity

These methodological considerations should be adapted based on the specific research question and tissue types being examined.

What are the current limitations of TRMT12 antibody research and potential future developments?

Despite significant progress in the development and validation of TRMT12 antibodies, several limitations remain that should inform both current research and future antibody development efforts:

• Current Limitations:

  • Limited validation across diverse tissue types beyond cancer cell lines

  • Incomplete characterization of antibody performance for detecting potential TRMT12 isoforms

  • Scarcity of antibodies specifically designed to detect post-translational modifications

  • Minimal cross-validation between different commercial antibodies

  • Few antibodies with validated performance across multiple applications (WB, ICC, IHC, IP)

• Emerging Methodologies:

  • Recombinant antibody technologies may improve batch-to-batch consistency

  • Nanobodies or other alternative binding proteins could offer improved access to conformational epitopes

  • CRISPR-based tagging of endogenous TRMT12 may provide alternative validation approaches

  • Integration with spatial transcriptomics for contextualizing TRMT12 expression patterns

• Future Research Directions:

  • Development of antibodies targeting specific functional domains of TRMT12

  • Characterization of TRMT12 interaction networks through proximity labeling approaches

  • Investigation of TRMT12's role in disease contexts beyond cancer

  • Exploration of potential TRMT12 isoforms and their functional significance

• Technological Advances:

  • Single-cell protein analysis methods may reveal cell-to-cell variation in TRMT12 expression

  • Improved methods for studying enzyme-substrate interactions could clarify TRMT12's catalytic mechanism

  • Integration with the growing data from large-scale genomic initiatives like the All of Us Research Program